Mitsubishi Tanabe Pharma

Mitsubishi Tanabe Pharma Overview

Company Headquarters: Japan

Founded: 1678

Workforce: ~ 69,784

Revenue: USD 34.64 Billion

Company Working: Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures, and commercializes ethical drugs and over the counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders, and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tanabe also offers major products for skin conditions and digestive medicines. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe, and North America. Mitsubishi Tanabe is headquartered in Osaka, Japan.

Strategy

Mitsubishi Tanabe Pharma Corporation is a Japanese pharmaceutical company that focuses on the research, development, and commercialization of pharmaceuticals and medical devices. The company's strategy includes the following:

Research and Development: Mitsubishi Tanabe Pharma Corporation invests heavily in research and development to discover new drugs and medical devices. The company's R&D efforts focus on developing innovative drugs to address unmet medical needs in areas such as neurology, oncology, and immunology.Strategic Partnerships: Mitsubishi Tanabe Pharma Corporation has established partnerships with leading research institutions and pharmaceutical companies worldwide. These partnerships help the company to expand its research capabilities, access new technologies, and strengthen its pipeline of drugs and medical devices.Global Expansion: Mitsubishi Tanabe Pharma Corporation is expanding its global footprint through partnerships, acquisitions, and strategic investments. The company is focused on increasing its presence in key markets such as the United States and Europe, where it sees significant growth opportunities.Patient-Centered Approach: Mitsubishi Tanabe Pharma Corporation places a strong emphasis on patient-centricity, which means putting patients at the center of everything they do. The company's goal is to develop drugs and medical devices that meet the specific needs of patients and improve their quality of life.

Company Snapshot

$3.5M

Revenue

69,784

Employees

1678

Founded

Japan

Headquarters

SWOT Analysis

Strengths

Strong R&D investments
Focus on R&D Activities
Established Domestic Presence
Product Portfolio

Weaknesses

Overdependence on the pharmaceutical segment
Cost Efficiency

Opportunities

Promising Pipeline Products
Contracts and Agreements
Market Potential – CNS Therapy

Threats

Uncertain R&D Outcomes
Competitive Environment
Government Regulations

Key Developments

Date	Approach	Development
October 2019	Acceptance of New Drug Submission	Medicago Inc., the affiliated company of Mitsubishi, received acceptance for new drug submission for a plant-based quadrivalent virus-like particle (VLP) influenza recombinant vaccine for scientific review.
March 2018	Collaboration	Mitsubishi and Hitachi entered into a partnership for improving efficiency of clinical trials for new drug development using AI technology.
September 2017	Clinical Trial Initiation	Medicago Inc., the affiliated company of Mitsubishi, initiated the Phase III clinical study for its seasonal quadrivalent influenza vaccine candidate, in Canada, the US, Europe, and Asia.

Product Offering

Mitsubishi Tanabe Pharma
- Influenza Vaccine
- Plasma Fractionation Market

Financial Performance

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.